USFDA issues EIR with NAI classification for Alivus Life Sciences’ API unit

28 Jul 2025 Evaluate

The United States Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) classification for Alivus Life Sciences’ API Manufacturing facility at Dahej, Gujarat. The USFDA had conducted an inspection from May 26, 2025 to May 30, 2025. 

Alivus Life Sciences (Formally known as Glenmark Life Sciences) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. 

Alivus Life Sciences Share Price

880.35 -7.10 (-0.80%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×